 The primary objective of the SRD part trial part 1 is to investigate the safety and tolerability of BI 730357 in healthy subjects following oral administration of single rising doses after fasting andor non-fasting conditions. The secondary objective is the exploration of the pharmacokinetics PK including dose proportionality, and pharmacodynamics of BI 730357 after single dosing. 